Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6838155 | 1.00 | POLB (0.36) | POLBCAPN1NPC1RAB9ACTSD | |
| SCHEMBL3806061 | 0.93 | FPR2 (0.37) | NPC1RAB9AUSP2KMT2A | |
| SCHEMBL3797429 | 0.87 | DPP4 (0.38) | — | |
| SCHEMBL3803345 | 0.87 | DPP4 (0.38) | — | |
| SCHEMBL7432732 | 0.84 | ATM (0.46) | LMNAACEKMT2A | |
| SCHEMBL6312228 | 0.84 | ATM (0.46) | LMNAACEKMT2A | |
| SCHEMBL7443701 | 0.84 | ATM (0.46) | LMNAACEKMT2A | |
| SCHEMBL9005035 | 0.84 | ATM (0.46) | LMNAACEKMT2A | |
| SCHEMBL4061133 | 0.84 | CAPN1 (0.35) | CAPN1NPC1RAB9ABACE1KMT2A | |
| SCHEMBL9817901 | 0.84 | CACNA1G (0.39) | NPC1RAB9AACECACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6753410-B2 | ANALYZING THE PROCESSING OF AMYLOID PROTEIN PRECURSOR (APP); ALZHEIMER'S DISEASE; ENZYME INHIBITORS OF GAMMA-SECRETASE, A PROTEASE, AND INHIBITS PROTEOLYSIS OF PRESENILIN-1 ON WHICH THE SECRETASE ACTIVITY IS DEPENDENT | MERCK & CO., INC. | 2004-06-22 | — | — | US | disclosed |
| US-20020013276-A1 | Investigational compounds | MERCK & CO., INC. | 2002-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013276-A1 | Investigational compounds | CBR1, CBR3, CNR1 | POLB 2576/4885CAPN1 2919/4885NPC1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.